- Home
- CHPT vs AURA Comparison
CHPT vs AURA Comparison
Compare CHPT & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHPT
- AURA
- Stock Information
- Founded
- CHPT 2007
- AURA 2007
- Country
- CHPT United States
- AURA United States
- Employees
- CHPT N/A
- AURA N/A
- Industry
- CHPT Industrial Specialties
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- CHPT Consumer Discretionary
- AURA Health Care
- Exchange
- CHPT Nasdaq
- AURA Nasdaq
- Market Cap
- CHPT 340.1M
- AURA 396.8M
- IPO Year
- CHPT N/A
- AURA 2021
- Fundamental
- Price
- CHPT $0.66
- AURA $6.49
- Analyst Decision
- CHPT Hold
- AURA Strong Buy
- Analyst Count
- CHPT 10
- AURA 6
- Target Price
- CHPT $1.46
- AURA $22.33
- AVG Volume (30 Days)
- CHPT 17.8M
- AURA 223.9K
- Earning Date
- CHPT 09-03-2025
- AURA 08-07-2025
- Dividend Yield
- CHPT N/A
- AURA N/A
- EPS Growth
- CHPT N/A
- AURA N/A
- EPS
- CHPT N/A
- AURA N/A
- Revenue
- CHPT $407,681,000.00
- AURA N/A
- Revenue This Year
- CHPT $3.54
- AURA N/A
- Revenue Next Year
- CHPT $26.21
- AURA N/A
- P/E Ratio
- CHPT N/A
- AURA N/A
- Revenue Growth
- CHPT N/A
- AURA N/A
- 52 Week Low
- CHPT $0.51
- AURA $4.35
- 52 Week High
- CHPT $2.44
- AURA $12.38
- Technical
- Relative Strength Index (RSI)
- CHPT 39.96
- AURA 59.68
- Support Level
- CHPT $0.67
- AURA $5.96
- Resistance Level
- CHPT $0.73
- AURA $6.68
- Average True Range (ATR)
- CHPT 0.05
- AURA 0.36
- MACD
- CHPT -0.01
- AURA 0.01
- Stochastic Oscillator
- CHPT 0.47
- AURA 97.70
About CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.